Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Novartis Seeks Japan Approval for 2 Malignant Melanoma Drugs Transferred from GSK
April 28, 2015
- Eisai, Nihon Medi-Physics Tie Up for Diagnosis, Treatment of Dementia with Lewy Bodies
April 28, 2015
- Opdivo Gains Positive CHMP Opinion for Advanced Melanoma
April 27, 2015
- Takeda’s Shonan Lab Collaborative Research Initiative Forging Ahead
April 27, 2015
- Janssen Files Risperdal for Irritability Associated with Autistic Disorder in Children
April 27, 2015
- Eisai Launches 2 Anticancer Agents in Mexico
April 27, 2015
- Bayer Seeks Japan Approval of Prostate Cancer Drug Radium-223 Dichloride
April 27, 2015
- Sumitomo Dainippon Faces Dim Prospects for Lurasidone Filing in Japan
April 27, 2015
- Astellas Sees 59% Rise in FY2014 Operating Profit
April 24, 2015
- Strategia Therapeutics Starts PI/IIa Study of Anticancer Agent Licensed from Eisai in US
April 24, 2015
- Sales Rep Survey – Part 3: Chugai, Takeda Raise Base Salaries, Reflecting “Social Trend”
April 24, 2015
- Astellas Links Up with US Biotech Potenza on Immuno-Oncology
April 23, 2015
- Shionogi Ups FY2014 Earnings Outlook on ViiV Dividends
April 23, 2015
- Ono Seeks Lung Cancer Indication for Opdivo in Japan
April 23, 2015
- Sales Rep Survey - Part 2: Japanese Drug Makers Forging Specialized Forces in Oncology
April 23, 2015
- Daiichi Sankyo Sells All Shares of Sun Pharma
April 22, 2015
- Merck KGaA, Pfizer Start Multinational PIII Study of Anti-PD-L1 Antibody Avelumab
April 22, 2015
- Sales Rep Survey - Part 1: Decreases in Reps Prominent in Major Firms, Is Field Force Strategy at Turning Point?
April 22, 2015
- Nissan Chemical Loses Livalo Patent Suits against 8 Firms
April 21, 2015
- Asahi Kasei Pharma Pulls Plug on Liquid Diet Biz
April 21, 2015
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…